This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beaulieu, A. J. Articles by Bostom, A. G. Search for Related Content PubMed PubMed Citation Articles by Beaulieu, A. J. Articles by Bostom, A. G. Related Collections Cardiovascular Pharmacology Other etiology Epidemiology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2918.)
© 1999 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Enhanced Reduction of Fasting Total Homocysteine Levels With Supraphysiological Versus Standard Multivitamin Dose Folic Acid Supplementation in Renal Transplant Recipients

Andrew J. Beaulieu; Reginald Y. Gohh; Haewook Han; David Hakas; Paul F. Jacques; Jacob Selhub; Andrew G. Bostom
Abstract—The mild fasting hyperhomocysteinemia commonly observed in chronic (ie, 6 months posttransplantation) renal transplant recipients (RTRs) can be effectively treated with combined B-vitamin supplementation featuring supraphysiological doses of folic acid. There are no controlled data evaluating the comparative efficacy of supraphysiological versus standard multivitamin dose folic acid supplementation in reducing fasting total homocysteine (tHcy) levels among RTRs. We block-randomized 60 chronic, stable RTRs on the basis of their screening fasting tHcy level to 3 groups of 20 subjects treated for 12 weeks with folic acid at either 2.4 (group 1), 0.4 (ie, standard multivitamin dose) (group 2), or 0.0 (group 3) mg/d. All 60 study participants also received 50 mg/d vitamin B₆ and 0.4 mg/d vitamin B₁₂. The mean percent reductions (±SEM) in fasting tHcy were as follows: group 1, 32.3±2.4%; group 2, 23.4±2.3%; and group 3, 19.1±2.3%. ANCOVA accounting for the pretreatment matching and adjusted for pretreatment levels of fasting tHcy, folate, and albumin; change in creatinine during the study; and cyclosporine A use revealed significant overall group differences (P=0.005) and significant differences between groups 1 and 2 (P=0.038) and groups 1 and 3 (P=0.001), but not between groups 2 and 3 (P=0.153). Moreover, a ² analysis of participants with pretreatment tHcy levels 15 µmol/L (n=29) indicated that a significantly greater proportion of those in group 1 achieved posttreatment levels <12 µmol/L: group 1, 5 of 10 (50%); group 2, 1 of 11 (9%); and group 3, 0 of 8 (0%) (P=0.016; test of trend P=0.007). We conclude that a supraphysiological dose of folic acid is superior to standard multivitamin dosing for the reduction of fasting tHcy levels in chronic RTRs.

Key Words: hyperhomocysteinemia • renal insufficiency • treatment • controlled trial

This article has been cited by other articles:

				C. J. Abularrage, A. N. Sidawy, P. W. White, G. Aidinian, K. J. DeZee, J. M. Weiswasser, and S. Arora Effect of Folic Acid and Vitamins B6 and B12 on Microcirculatory Vasoreactivity in Patients With Hyperhomocysteinemia Vascular and Endovascular Surgery, September 1, 2007; 41(4): 339 - 345. [Abstract] [PDF]

				O. Bleie, H. Refsum, P. M. Ueland, S. E. Vollset, A. B. Guttormsen, E. Nexo, J. Schneede, J. E. Nordrehaug, and O. Nygard Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention Am. J. Clinical Nutrition, September 1, 2004; 80(3): 641 - 648. [Abstract] [Full Text] [PDF]

				A. N. FRIEDMAN, A. G. BOSTOM, J. SELHUB, A. S. LEVEY, and I. H. ROSENBERG The Kidney and Homocysteine Metabolism J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2181 - 2189. [Abstract] [Full Text] [PDF]

				A. G. Bostom, J. Selhub, P. F. Jacques, and I. H. Rosenberg Power Shortage: Clinical Trials Testing the "Homocysteine Hypothesis" against a Background of Folic Acid-Fortified Cereal Grain Flour Ann Intern Med, July 17, 2001; 135(2): 133 - 137. [Abstract] [Full Text] [PDF]

				O. Aras, M. Y. Tsai, N. Q. Hanson, R. Bailey, G. Rao, and D. B. Hunninghake Cystatin C Is an Independent Predictor of Fasting and Post-Methionine Load Total Homocysteine Concentrations among Stable Renal Transplant Recipients Clin. Chem., July 1, 2001; 47(7): 1263 - 1268. [Abstract] [Full Text] [PDF]

				L.-N. Chan Drug-Nutrient Interactions in Transplant Recipients JPEN J Parenter Enteral Nutr, May 1, 2001; 25(3): 132 - 141. [Abstract] [PDF]

				A. G. Bostom, D. Shemin, P. Bagley, Z. A. Massy, A. Zanabli, K. Christopher, P. Spiegel, P. F. Jacques, L. Dworkin, and J. Selhub Controlled Comparison of L-5-Methyltetrahydrofolate Versus Folic Acid for the Treatment of Hyperhomocysteinemia in Hemodialysis Patients Circulation, June 20, 2000; 101(24): 2829 - 2832. [Abstract] [Full Text] [PDF]